Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class ASSE: 603392

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on the Company's 9-Valent HPV Vaccine Obtaining Marketing Authorization in Thailand

Aug 12, 2026 · Issued by Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on the Company's 9-Valent HPV Vaccine Obtaining Marketing Authorization in Thailand

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Resolutions of the 18th Meeting of the 6th Board of DirectorsAug 8
"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Acceptance of the Clinical Trial Application for the Company's Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)Jul 21
"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Expected Loss in Semi-annual Performance for 2026Jul 15
"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on the Resignation of a Director and General Manager and the Chairman's Assumption of the General Manager's DutiesJul 4

All Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A news releases